Patients with IBD in remission who switch from infliximab to a biosimilar, CT-P13, have non-inferior clinical outcomes to those who remain on the originator, Australian data show.

The Switching Australian patients with Moderate to Severe inflammatory bowel diseasE (SAME) study  included 345 adults (232 with Crohn’s disease) being treated with infliximab who had been in stable clinical or biochemical remission, free of steroids, for at least 12 weeks.

They were allocated either to remain on infliximab (Remicade, Janssen-Cilag) or to switch to the CT-P13 biosimilar (Inflectra, Pfizer) according to the hospital they attended.

A total of 204 patients were switched to the biosimilar at four public hospitals – Fiona Stanley Hospital in Perth, Box Hill Hospital in Melbourne, St Vincent’s Hospital in Sydney and the Mater Hospital in Brisbane.